Skip to main content

Table 5 Comparison of the effects of dapagliflozin on metabolic parameters with or without renal dysfunction

From: A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

Variables

Dapagliflozin (n = 14)

p value

eGFR ≥ 70

[mL min−1 (1.73 m2)−1]

(n = 6)

eGFR < 70

[mL min−1 (1.73 m2)−1]

(n = 8)

ΔMAGE (mg dL−1)

−3.4 ± 24.1

11.4 ± 31.9

0.34

ΔHbA1c (%)

0.3 ± 0.7

0.6 ± 0.4

0.35

ΔBMI (kg m−2)

−1.2 ± 0.4

−0.7 ± 1.1

0.31

  1. Values are mean ± SD. p value of eGFR ≥ 70 vs eGFR < 70
  2. eGFR estimated glomerular filtration rate, MAGE mean amplitude of glycemic excursions, BMI body mass index
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us